- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05379686
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes (The HYPO-AVOID)
April 17, 2024 updated by: Steno Diabetes Center Copenhagen
The primary aim of the study is to evaluate the glucose response to low-dose glucagon (single 150 µg dose) administered immediately before aerobic exercise in individuals with AHCL-treated T1D.
Study Overview
Detailed Description
The study consists of a screening visit (visit A) and two additional study visits (visit B and visit C) completed in a sequential order.
During study visit B participants will receive s.c.
administration of 150 ug glucagon prior to a 45-min moderate intensity continuous exercise session and subsequently continue into a 1-hour post-exercise observation period.
During study visit C the exact same procedures will be followed with the omission of glucagon.
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sissel B Lundemmose, MD
- Phone Number: 0045 24846602
- Email: sissel.lundemose@regionh.dk
Study Locations
-
-
-
Herlev, Denmark, 2730
- Recruiting
- Steno Diabetes Center Copenhagen
-
Contact:
- Sissel B Lundemose, MD
- Phone Number: +4524846602
- Email: sissel.lundemose@regionh.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 years
- Type 1 diabetes ≥ 2 years
- Use of AHCL system MiniMed 780G ≥ 4 weeks
- Use of Novorapid for ≥ 1 week
Exclusion Criteria:
- Allergies to lactose or glucagon
- Known or suspected allergies to glucagon or related products
- History of hypersensitivity or allergic reaction to glucagon or lactose
- Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis
- Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
- Lack of compliance with key study procedures at the discretion of the investigator
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (>12 months since last period) are not required to use contraception)
- Inability to understand the individual information and to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 150 ug glucagon before exercise
150 ug glucagon will be administered subcutaneously just before exercise
|
150 ug glucagon will be administered to the participants before exercise.
Other Names:
|
No Intervention: Control
No glucagon will be administered before exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in incidence rate of hypoglycaemic events (PG<3.9 mmol/l) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in time (min) to hypoglycaemia (PG<3.9 mmol/l) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in percentage of time below target glucose range (PG<3.9 mmol/l) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in percentage of time above target glucose range (PG>10.0 mmol/l) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in incidence rate of hyperglycaemia (PG>10.0 mmol/l) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in nadir PG concentration between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in peak PG concentration between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in incremental peak PG concentration between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in mean PG concentration between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in PG Area Under the Curve (AUC) between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in standard deviation in PG concentrations between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Difference in Coefficient of variation in PG concentrations between visit B and C
Time Frame: 0 min to +105 min
|
0 min to +105 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sissel B Lundemose, MD, Steno Diabetes Center Copenhagen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2022
Primary Completion (Estimated)
May 13, 2024
Study Completion (Estimated)
May 13, 2024
Study Registration Dates
First Submitted
May 12, 2022
First Submitted That Met QC Criteria
May 12, 2022
First Posted (Actual)
May 18, 2022
Study Record Updates
Last Update Posted (Actual)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 17, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Glucagon
Other Study ID Numbers
- 85256
- 2021-004993-68 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoglycemia
-
University of UlmRecruitingHypoglycemia, ReactiveGermany
-
University of ArizonaNot yet recruiting
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Zealand University HospitalUnknownHypoglycemia, ReactiveDenmark
-
MBX BiosciencesProSciento, Inc.RecruitingPostbariatric HypoglycemiaUnited States
-
University Hospital, Basel, SwitzerlandBoehringer IngelheimRecruitingPostprandial HypoglycemiaSwitzerland
-
University of NebraskaCompletedNeonatal HypoglycemiaUnited States
-
Vogenx, Inc.CompletedPostbariatric HypoglycemiaUnited States
-
Stanford UniversityCompletedNeonatal HypoglycemiaUnited States
-
Diva De LeonLester and Liesel Baker FoundationCompletedPostprandial HypoglycemiaUnited States
Clinical Trials on GlucaGen
-
Zealand PharmaSynteractHCRCompletedHypoglycemia | Diabetes Mellitus, Type 1United States, Austria, Canada, Germany
-
Zealand PharmaCompletedHypoglycemia | Diabetes Mellitus, Type 1Canada, United States, Austria, Germany
-
Charite University, Berlin, GermanyUnknownObesity | Diabetes Mellitus, Type 1 | Healthy SubjectsGermany
-
Steno Diabetes Center CopenhagenCompletedHypoglycemia | Type 1 DiabetesDenmark
-
Université Catholique de LouvainFonds National de la Recherche Scientifique; BESPEEDActive, not recruitingType1diabetesBelgium
-
Steno Diabetes Center CopenhagenUniversity of CopenhagenCompletedDiabetes Mellitus | Non-Alcoholic Fatty Liver Disease | Total PancreatectomyDenmark
-
Legacy Health SystemJuvenile Diabetes Research Foundation; Oregon Health and Science UniversityCompletedType 1 Diabetes MellitusUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Germany
-
Inreda Diabetic B.V.WithdrawnDiabetes Mellitus, Type 1Netherlands
-
Legacy Health SystemJuvenile Diabetes Research Foundation; Oregon Health and Science UniversityCompleted